Yang, Shuying
Lee, Laurie A.
Sule, Neal
Fowler, Andrew
Peachey, Guy
Funding for this research was provided by:
GlaxoSmithKline (GSK 205715)
Article History
Accepted: 16 January 2021
First Online: 18 February 2021
Declarations
:
: This work was funded by the GlaxoSmithKline (study number GSK 205715), NCT02924688.
: SY, NS, AF, and GP are all employees of GlaxoSmithKline (GSK) and own stocks and shares in the company. LAL was an employee of GSK at the time of this study. GP also owns stocks and shares in Novartis.
: This study was conducted in accordance with the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice, and applicable country-specific regulatory requirements. The protocol received approval from applicable central or local Institutional Review Boards or independent Ethics Committees.
: Written informed consent was obtained from all participants before participation.
: Not applicable.
: Anonymized individual participant data and study documents can be requested for further research from ExternalRef removed.
: Not applicable.
: The authors meet the criteria for authorship as recommended by the International Committee of Medical Journal Editors, take responsibility for the integrity of the work as a whole, contributed to the writing and reviewing of the manuscript, and have given final approval for the version to be published. All authors had full access to the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. SY, LL, and GP were involved in the conception and design of the study and the data analysis and interpretation. AF and NS were involved in the data analysis and interpretation.